The evolving paradigm of cancer trials

Article metrics

The development of anticancer therapies is evolving with the advent of novel targeted drugs. In this Comment, I summarize some of the key changes and discuss the various choices for the optimal development of a new generation of cancer therapeutics.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Kummar, S. et al. Establishing proof of mechanism: assessing target modulation in early-phase clinical trials. Semin. Oncol. 43, 446–452 10.1053/j.seminoncol.2016.06.002 (2016).

  2. 2

    Prowell, T. M., Theoret, M. R. & Pazdur, R. Seamless oncology-drug development. N. Engl. J. Med. 374, 2001–2003 (2016).

  3. 3

    Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693–1703 (2010).

  4. 4

    Hyman, D. M. et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N. Engl. J. Med. 373, 726–736 (2015).

  5. 5

    Le Tourneau, C. et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 16, 1324–1334 (2015).

Download references

Author information

Correspondence to Shivaani Kummar.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kummar, S. The evolving paradigm of cancer trials. Nat Rev Drug Discov 17, 225–226 (2018) doi:10.1038/nrd.2017.210

Download citation